Suchergebnisse

AbstractObjectiveTo assess survival and success rates of dental implants and the occurrence of peri‐implant diseases (mucositis/peri‐implantitis) in HIV‐1‐infected individuals.Material and methodsIn this prospective study, 13 HIV‐1‐infected individuals undergoing highly active antiretroviral therapy (with undetectable plasma HIV RNA levels, and CD4+ T cells > 350/mm3) were followed after implant placement, as well as 13 non‐HIV‐1‐infected matched controls. Patients enrolled in this study were followed up to 120 months (mean = 40.6 months; standard deviation = 22.2; range 18 –120 months). Twenty‐five implants were placed in pristine healed sites for each group and bone augmentation procedures, when needed, were done only for contour augmentation. Patients were enrolled in a strict periodontal/peri‐implant supportive therapy protocol with three recalls per year. The two groups were compared regarding subject‐level characteristics (age, gender, smoking, diabetes) and implant‐level characteristics (marginal bone level, peri‐implant health status).ResultsAll the implants healed uneventfully and reached 100% survival rates (after at least 18 months) in both groups. There were no significant differences between groups for peri‐implant diseases (mucositis/peri‐implantitis) and for all subject‐level co‐variables (p > .05). Only the variables dental implant prosthesis type (DIPT) (p = .021, d = .86) and follow up (p = .011, d = .77) showed statistically significant differences between groups.ConclusionThe findings suggest that well‐controlled HIV‐1‐infected individuals are eligible to undergo implant therapy, achieving survival and success rates comparable to non‐HIV‐1‐infected controls.